SG Americas Securities LLC Grows Stock Position in Castle Biosciences, Inc. $CSTL

SG Americas Securities LLC boosted its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 1,051.8% during the 1st quarter, Holdings Channel.com reports. The firm owned 244,886 shares of the company’s stock after acquiring an additional 223,624 shares during the period. SG Americas Securities LLC’s holdings in Castle Biosciences were worth $6,012,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Federated Hermes Inc. purchased a new position in shares of Castle Biosciences in the 4th quarter valued at about $26,000. Kemnay Advisory Services Inc. acquired a new stake in Castle Biosciences in the fourth quarter valued at approximately $35,000. Jones Financial Companies Lllp raised its holdings in Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after acquiring an additional 2,648 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Castle Biosciences by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock worth $55,000 after acquiring an additional 297 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in Castle Biosciences by 256.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,791 shares of the company’s stock worth $57,000 after acquiring an additional 2,009 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Roth Mkm started coverage on shares of Castle Biosciences in a report on Wednesday. They issued a “buy” rating and a $40.00 price objective on the stock. Weiss Ratings lowered Castle Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 1st. Wall Street Zen cut Castle Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Robert W. Baird decreased their price target on Castle Biosciences from $44.00 to $43.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, Zacks Research cut Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.43.

Castle Biosciences Stock Performance

NASDAQ CSTL opened at $24.30 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 6.53. Castle Biosciences, Inc. has a 1 year low of $14.59 and a 1 year high of $44.28. The company has a market capitalization of $737.02 million, a PE ratio of -55.23 and a beta of 1.04. The company has a fifty day moving average of $21.60 and a two-hundred day moving average of $29.06.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Wednesday, May 6th. The company reported ($0.49) earnings per share for the quarter, meeting the consensus estimate of ($0.49). The business had revenue of $84.23 million during the quarter, compared to the consensus estimate of $79.23 million. Castle Biosciences had a negative return on equity of 2.77% and a negative net margin of 3.78%. As a group, analysts expect that Castle Biosciences, Inc. will post -1.48 earnings per share for the current year.

Insider Buying and Selling at Castle Biosciences

In related news, insider Derek J. Maetzold sold 3,622 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $20.66, for a total transaction of $74,830.52. Following the transaction, the insider owned 12,646 shares of the company’s stock, valued at $261,266.36. This trade represents a 22.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Kristen M. Oelschlager sold 8,587 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $20.71, for a total value of $177,836.77. Following the completion of the transaction, the chief operating officer owned 30,460 shares in the company, valued at $630,826.60. This trade represents a 21.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 40,775 shares of company stock valued at $916,887. 6.10% of the stock is owned by insiders.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.